F2G; Shionogi; olorofim; Boehringer Ingelheim; GSK; Arcellx; Gilead; Sensorion; BioSenic; Medsenic; Zantac; CART-ddBCMA
Today in FirstWord Pharma 's Industry News newsletter, we cover:
? FDA declines to approve Shionogi, F2G's antifungal olorofim
?? Arbitration court rejects Boehringer's indemnification claim against Sanofi in Zantac litigation
?? Patient death triggers FDA clinical hold on Gilead, Arcellx's BCMA-directed CAR-T
?? Sensorion touts early data for SENS-401 following cochlear implantation
?? BioSenic hits pause on trial of bone-forming cell therapy ALLOB
?? To learn more about these top stories, sign up to receive our newsletter ?? https://firstwordpharma.com/register and never miss the important news and insights impacting the?#pharma?industry!